Sepsis

Blood culture contamination remains a persistent challenge in healthcare, impacting patient care and outcomes, and driving up costs. As awareness grows, blood culture kitting has emerged as a practical solution to improve sample collection by standardizing supplies, simplifying decision-making, and reducing waste.

A study shows source-specific antibiotic order sets in emergency care improve empiric treatment decisions for sepsis and support timely patient management.

A study from The University of Manchester highlights how socioeconomic factors increase mortality risk in non-COVID sepsis, stressing targeted prevention.

A new study with the UK Sepsis Trust explores barriers to sepsis care bundle adherence in Europe and offers insights to improve sepsis management strategies.

A clinical trial in West Africa tests whether intrapartum azithromycin reduces neonatal sepsis and mortality, with additional evaluation of infection and fever rates.

The SepSIGN trial aims to validate biomarkers that help predict early clinical worsening in adults admitted to the ED with suspected or confirmed infection.

Sepsis linked to opioid use is an overlooked crisis driving hospitalizations and harm, with experts urging strategies to address this growing public health issue.

Rapid detection of bloodstream infections like S. aureus is vital for sepsis care; automated blood culture systems deliver faster, more accurate results.

The Surviving Sepsis Campaign infographic highlights updated global guidelines on antibiotic timing, vasoactive agents, and septic shock care.

Balancing timely sepsis treatment with AKI risk, experts highlight how early biomarker assessment can guide safer, more effective antimicrobial use.

September is Sepsis Awareness Month, with resources and tools to help individuals and healthcare teams raise awareness and improve patient outcomes.

A systematic review shows COVID-19 ICU patients often meet sepsis criteria, highlighting the need for targeted treatments and policies for future pandemics.

Faster blood culture results are key to improving sepsis care by enabling early diagnosis and reducing mortality, costs, and antimicrobial resistance.

Biomarkers like procalcitonin and TIMP2-IGFBP7 improve sepsis and AKI diagnosis, helping to reduce organ failure and guide goal-directed therapy.

A podcast explores how new CAP guidelines view procalcitonin use alongside clinical judgment to guide antibiotic decisions in sepsis and respiratory care.